Relief Therapeutics and NeuroX Finalize Business Combination Agreement

Relief Therapeutics Holding SA and NeuroX Group SA have signed a definitive agreement to merge, creating a robust AI-driven health tech firm. Once finalized, the entity will rebrand as MindMaze Therapeutics Holding SA, enhancing its global influence in neurotherapeutic solutions. This merger integrates NeuroX's clinically validated digital neurotherapeutic expertise, allowing for precision medicine in neurology.

The combined company positions itself through a significant commercialization network spanning over 250 clinics while employing a proprietary neuro-data engine. They aim to address conditions like stroke and Parkinson’s more effectively. The anticipated merger is set to close in December 2025, subject to regulatory approvals.